A. M. Brufksy

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

B. Taylor, S. Loi, S. Chandarlapaty, 2019, Cancer discovery.

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Sung-Bae Kim, W. Gradishar, H. Wildiers, 2021, Clinical Cancer Research.